Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLaëtitia LargeaudLDLucie DonatyVMVéronique Mansat‐De Mas

Discussion

Loading...

Member takes

Overview

Registry study reveals minimal residual disease monitoring impacts survival outcomes and relapse risk in blood cancer patients.

Key Points

  • Evaluate the prognostic value of minimal residual disease assessment in patients with NPM1-mutated acute myeloid leukemia.
  • Analyzed data from 506 adults with NPM1-mutated AML in the DATAML registry.
  • Used flow cytometry and quantitative PCR to monitor minimal residual disease post-induction chemotherapy.
  • Identified distinct patient groups based on MRD assessment results.
  • Patients with positive minimal residual disease had lower survival rates compared to negative cases.
  • Cumulative incidence of relapse was significantly higher in MRD positive patients.
  • Four distinct prognostic groups were identified with varying three-year survival rates.

Cite This Study

Largeaud et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0bdhttps://doi.org/10.1182/blood-2025-1744
View Full Paper
Ask AI
Bookmark
Share